Cargando…

Mesenchymal stem cell–gut microbiota interaction in the repair of inflammatory bowel disease: an enhanced therapeutic effect

BACKGROUND: Several investigations affirm that, patients with inflammatory bowel disease (IBD) exhibit dysbiosis characterized by restricted biodiversity and imbalanced bacterial composition intertwined with immune dysregulation. The interaction between stem cells and gut microbiota is a novel and h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ocansey, Dickson Kofi Wiredu, Wang, Li, Wang, Jingyan, Yan, Yongmin, Qian, Hui, Zhang, Xu, Xu, Wenrong, Mao, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928179/ https://www.ncbi.nlm.nih.gov/pubmed/31872304 http://dx.doi.org/10.1186/s40169-019-0251-8

Ejemplares similares

The Achievements and Challenges of Mesenchymal Stem Cell-Based Therapy in Inflammatory Bowel Disease and Its Associated Colorectal Cancer
por: Ocansey, Dickson Kofi Wiredu, et al.
Publicado: (2020)

Improved therapeutics of modified mesenchymal stem cells: an update
por: Ocansey, Dickson Kofi Wiredu, et al.
Publicado: (2020)

Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy
por: Wang, Yifei, et al.
Publicado: (2022)

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease
por: Xu, Xinwei, et al.
Publicado: (2022)

Role of ferroptosis in the pathogenesis and as a therapeutic target of inflammatory bowel disease (Review)
por: Ocansey, Dickson Kofi Wiredu, et al.
Publicado: (2023)

The diagnostic and prognostic potential of gut bacteria in inflammatory bowel disease
por: Wiredu Ocansey, Dickson Kofi, et al.
Publicado: (2023)

Mucin-Type O-Glycans: Barrier, Microbiota, and Immune Anchors in Inflammatory Bowel Disease
por: Zhang, Yaqin, et al.
Publicado: (2021)

Human umbilical cord mesenchymal stem cells derived exosome shuttling mir-129-5p attenuates inflammatory bowel disease by inhibiting ferroptosis
por: Wei, Zhiping, et al.
Publicado: (2023)

The Emerging Clinical Application of m6A RNA Modification in Inflammatory Bowel Disease and Its Associated Colorectal Cancer
por: Xu, Xinwei, et al.
Publicado: (2021)

Cellular and molecular mediators of lymphangiogenesis in inflammatory bowel disease
por: Ocansey, Dickson Kofi Wiredu, et al.
Publicado: (2021)

The role of mesenchymal stem cell-derived exosome in epigenetic modifications in inflammatory diseases
por: Zhao, Zihan, et al.
Publicado: (2023)

Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease and colorectal cancer
por: Zhou, Mengjiao, et al.
Publicado: (2022)

Exosome‐mediated effects and applications in inflammatory bowel disease
por: Ocansey, Dickson K. W., et al.
Publicado: (2020)

Role of glycolysis in inflammatory bowel disease and its associated colorectal cancer
por: Xia, Yuxuan, et al.
Publicado: (2023)

HucMSC‐exosomes carrying miR‐326 inhibit neddylation to relieve inflammatory bowel disease in mice
por: Wang, Gaoying, et al.
Publicado: (2020)

Regulatory Effect of Mesenchymal Stem Cells on T Cell Phenotypes in Autoimmune Diseases
por: Wei, Zhiping, et al.
Publicado: (2021)

The Effects of Mesenchymal Stem Cell on Colorectal Cancer
por: Yuan, Jintao, et al.
Publicado: (2021)

Resveratrol alleviates DSS-induced IBD in mice by regulating the intestinal microbiota-macrophage-arginine metabolism axis
por: Xu, Xinwei, et al.
Publicado: (2023)

Emerging roles of mesenchymal stem cell-derived exosomes in gastrointestinal cancers
por: Wang, Naijian, et al.
Publicado: (2022)

Mesenchymal stem cells and their therapeutic applications in inflammatory bowel disease
por: Mao, Fei, et al.
Publicado: (2017)

hucMSC-Ex Alleviates IBD-Associated Intestinal Fibrosis by Inhibiting ERK Phosphorylation in Intestinal Fibroblasts
por: Wang, Yifei, et al.
Publicado: (2023)

Therapeutic Advances of Stem Cell-Derived Extracellular Vesicles in Regenerative Medicine
por: Yin, Lei, et al.
Publicado: (2020)

Systematic Exposition of Mesenchymal Stem Cell for Inflammatory Bowel Disease and Its Associated Colorectal Cancer
por: Kang, Jingjing, et al.
Publicado: (2018)

Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Relieve Inflammatory Bowel Disease in Mice
por: Mao, Fei, et al.
Publicado: (2017)

The effect of students’ online learning experience on their satisfaction during the COVID-19 pandemic: The mediating role of preference
por: Li, Xinchao, et al.
Publicado: (2023)

The Gut Microbiota in the Pathogenesis and Therapeutics of Inflammatory Bowel Disease
por: Zuo, Tao, et al.
Publicado: (2018)

Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion
por: Shao, Xuejun, et al.
Publicado: (2022)

hucMSC-derived exosomes attenuate colitis by regulating macrophage pyroptosis via the miR-378a-5p/NLRP3 axis
por: Cai, Xiu, et al.
Publicado: (2021)

miR-374 mediates the malignant transformation of gastric cancer-associated mesenchymal stem cells in an experimental rat model
por: Ji, Runbi, et al.
Publicado: (2017)

Special Issue “Gut Microbiota, Inflammatory Bowel Diseases, and Therapeutic Targets”
por: Filidou, Eirini, et al.
Publicado: (2023)

Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease
por: Hu, Yongjia, et al.
Publicado: (2022)

Gut Microbiota in Inflammatory Bowel Disease
por: Shim, Jung Ok
Publicado: (2013)

The gut microbiota and inflammatory bowel disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2014)

The Gut Microbiota in Inflammatory Bowel Disease
por: Qiu, Peng, et al.
Publicado: (2022)

Inflammatory Bowel Diseases and Gut Microbiota
por: Haneishi, Yuri, et al.
Publicado: (2023)

Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease
por: Guo, Xue, et al.
Publicado: (2022)

Bifico relieves irritable bowel syndrome by regulating gut microbiota dysbiosis and inflammatory cytokines
por: Zhou, Yanlin, et al.
Publicado: (2022)

Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches
por: Alshehri, Dikhnah, et al.
Publicado: (2021)

hucMSCs Attenuate IBD through Releasing miR148b-5p to Inhibit the Expression of 15-lox-1 in Macrophages
por: Kang, Jingjing, et al.
Publicado: (2019)

Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease?
por: Nishida, Atsushi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g1qnikdcqpbm99p7kav9r4k1p4